Clinical trial NCT05998941: A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Official title: TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Cervical Cancer
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-08-21
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed persistent, recurrent or metastatic (International Federation of Gynecology and Obstetrics (FIGO) stage IVB) cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma;
* It is not suitable for radical treatment such as surgery, radiotherapy and concurrent chemoradiotherapy;
* No previous systemic therapy for persistent, recurrent or metastatic cervical cancer;
* Provide archived or freshly obtained tumor tissue samples within the past 2 years or provide traceable test reports;
* 18 years old ≤75 years old (calculated on the date of signing the informed consent); Eastern Cooperative Oncology Group (ECOG) score 0-1; Expected survival ≥3 months;
* At least one measurable lesion according to (Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria;
* The main organs function well and meet the following standards:

  1. Blood routine test criteria (in the case of no blood transfusion and no correction by hematopoietic stimulating factor drugs within 14 days before screening) : absolute neutrophil count (ANC) ≥1.5×109 /L; Platelet ≥100×109 /L; Hemoglobin ≥100 g/L.
  2. Blood biochemical tests should meet the following criteria: total bilirubin (TBIL) ≤2× upper limit of normal (ULN) (≤3×ULN in Gilbert syndrome patients); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN. If liver metastasis is present, ALT and AST≤5×ULN; Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥60 mL/min; Serum albumin (ALB) ≥30g/L.
  3. Urine routine examination criteria: urine routine indicated that urinary protein \<++; If urinary protein ≥++, it should be confirmed that 24-hour urinary protein quantification ≤1.0 g.
  4. Coagulation function test criteria: prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR) ≤1.5×ULN (no anticoagulant therapy).
  5. Thyroid stimulating hormone (TSH) ≤ ULN; If abnormal, T3 and T4 levels should be examined. If T3 and T4 levels are normal, they can be selected.
  6. Echocardiographic assessment: left ventricular ejection fraction (LVEF) ≥50%.
  7. 12-lead Electrocardiograph (ECG) assessment: Corrected QT interval prolongation (QTc)\<470ms (female).
* Female subjects of childbearing age should agree to use contraception (such as intrauterine device (IUD), birth control pill or condom) during the study period and within 6 months after the study. A negative serum or urine pregnancy test within 7 days prior to study entry and must be non-lactating.
* Subjects voluntarily participated in this study, signed informed consent, and had good compliance.

Exclusion Criteria:

* Tumor disease and medical history:

  1. Have developed or are currently suffering from other malignant tumors within 3 years. The following two cases were included: other malignant tumors treated by single surgery, achieving R0 resection and no recurrence or metastasis; Cured non-melanoma skin cancer, nasopharyngeal carcinoma, and superficial bladder tumors
  2. Other pathological types, such as mucinous adenocarcinoma, clear cell adenocarcinoma, neuroendocrine tumor;
  3. tumor infiltration into the bladder or rectum;
  4. Subjects with known central nervous system (CNS) metastases and/or carcinomatous meningitis;
  5. Patients whose imaging showed that the tumor had invaded important blood vessels or the investigators judged that the tumor was highly likely to invade important blood vessels during the follow-up study and cause fatal hemorrhage;
  6. Uncontrollable pleural, pericardial, or peritoneal effusions requiring repeated drainage.
* Previous anti-tumor therapy:

  1. Received the last concurrent chemoradiotherapy for radical surgery or postoperative adjuvant therapy within 3 months before the first medication; Received palliative radiotherapy within 2 weeks before the first dose;
  2. Previously received platinum-based dual agents or any other chemotherapy agents in concurrent chemoradiotherapy for radical purposes;
  3. Received Chinese patent medicine with anti-tumor indications specified in the National Medicinal Products Administration (NMPA) approved drug instructions within 2 weeks before the first drug use;
  4. Prior treatment with anti-angiogenic therapy, immune checkpoint inhibitor therapy, or any treatment targeting immune costimulatory factors, which target the immune mechanism of tumor immune action;
  5. Patients who received immunoregulatory drugs within 2 weeks before the first dose;
  6. Non-resolved toxicity of grade 1 or higher than Common Terminology Criteria for Adverse Events (CTCAE) due to any previous treatment, excluding alopecia, peripheral sensory impairment.
* Comorbidities and medical history:

  a. Decompensated cirrhosis and active hepatitis; b. Kidney abnormalities: i. Renal failure requiring hemodialysis or peritoneal dialysis; ii. Presence of clinically significant hydronephrosis that, in the judgment of the investigator, cannot be resolved by nephrostomy or ureteral stent placement.

  c. Cardiovascular and cerebrovascular abnormalities: i. Myocardial ischemia or myocardial infarction occurred within half a year; ≥ class 2 Congestive heart failure of New York Heart Association (NYHA); Arterial thrombotic events block ≥ Grade 2; Arrhythmias that cannot be stably controlled with drugs and those that may potentially affect the trial treatment; ii. Arterial thrombotic events / venous thrombotic events, such as cerebrovascular accident, deep vein thrombosis, and pulmonary embolism, occurred within 6 months; iii. Patients with poor blood pressure control after standard treatment; iv. Previous history of myocarditis or cardiomyopathy. d. Gastrointestinal abnormalities: i. Active or documented inflammatory bowel disease, active diverticulitis; ii. Gastrointestinal perforation, fistula, and intra-abdominal abscess occurred within 6 months before the first medication; iii. The presence of clinical manifestations of gastrointestinal obstruction or the need for routine parenteral rehydration, parenteral nutrition, or indwelling gastric tube.

  e. History of immunodeficiency: i. A history of immunodeficiency, including Human Immunodeficiency Virus (HIV) positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; ii. Active autoimmune disease requiring systemic therapy occurred within 2 years before the first dose. Alternative therapies are not considered systemic treatments; iii. is diagnosed with immunodeficiency or is receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (at a dose \>10mg/ day of prednisone or other iso-efficacy hormone) and continues to use it within 2 weeks of the first dose.

  f. Risk of bleeding: i. Bleeding, clotting disease, or current use of warfarin, aspirin, or other antiplatelet drugs within 28 days before the first dose; ii. Patients with any history of bleeding or coagulopathy, regardless of severity; iii. Major surgical treatment or significant traumatic injury within 28 days prior to the first dose, or locally invasive procedure within 1 week), or elective major surgical treatment required during the study; iv. Wounds or fractures that have not healed for a long time. g. Poorly controlled diabetes: fasting blood glucose (FBG) \> 10mmol/L; h. Severe active or uncontrolled infection (≥CTC AE grade 2 infection); i. People with known active syphilis and active tuberculosis; j. Previous or existing interstitial pneumonia, (non-infectious) pneumonia requiring corticosteroid therapy, or other pneumonia of grade ≥2; k. Severe hypersensitivity reaction after the use of monoclonal antibodies; l. Known to have any contraindications to cisplatin/carboplatin or paclitaxel or to be allergic to any of their components; m. Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders; n. Those who suffer from epilepsy and need treatment.
* Those who participated in clinical trials of other anti-tumor drugs within 4 weeks before the first drug use or did not exceed 5 drug half-lives.
* History of live attenuated vaccine vaccination within 28 days before the first dose or planned live attenuated vaccine vaccination during the study period.
* According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or there are other reasons that the subjects are not suitable for enrollment.

Primary outcomes:
measure: Investigator-assessed objective response rate (ORR)
timeFrame: Baseline to CR or PR ,about 12 months
Secondary outcomes:
measure: Progression free survival (PFS)
timeFrame: Baseline up to PD or death, about 24 months
measure: Disease control rate (DCR)
timeFrame: Baseline up to PD or death, about 24 months
measure: Duration of response (DOR)
timeFrame: Baseline up to PD or death, about 24 months
measure: Overall survival (OS)
timeFrame: Baseline up to die, about 36 months
measure: PFS rate (≥6 months)
timeFrame: Baseline up to PD or death, about 24 months
measure: Adverse event rate
timeFrame: Baseline to the end of the study, about 2 years
measure: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (QLQ -C30)
timeFrame: Baseline to the end of the study, about 2 years
measure: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ -CX24)
timeFrame: Baseline to the end of the study, about 2 years
measure: EuroQol 5 Dimensions (EQ-5D) Health questionnaire
timeFrame: Baseline to the end of the study, about 2 years
measure: PD-L1 and TGF-β expression
timeFrame: At baseline
measure: Human papillomavirus (HPV) expression
timeFrame: At baseline
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital
state: Chongqing
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
state: Fujian
Study officials:
References: